Literature DB >> 9618077

A longitudinal study of seroreactivity against Mycoplasma penetrans in HIV-infected homosexual men: association with disease progression.

O Grau1, P Tuppin, B Slizewicz, V Launay, C Goujard, E Bahraoui, J F Delfraissy, L Montagnier.   

Abstract

We investigated the relationships between a putative cofactor of HIV infection, Mycoplasma penetrans, and the evolution of HIV disease. The evolution of titers of anti-M. penetrans antibodies in 58 randomly selected HIV-seropositive adult homosexual men was investigated. The median length of follow-up was 38 months. Thirty-six individuals was investigated. The median length of follow-up was 38 months. Thirty-six individuals (62.1%) remained M. penetrans seronegative (group 0). Fourteen patients (24.1%) had consistently low antibody titers or low antibody titer(s) in at least one sample and negative test(s) in the other(s). This pattern was possibly associated with latent or earlier infection (group 1). Eight patients (13.8%) had moderate to high antibody titers for long periods, indicating an active and persistent M. penetrans infection (group 2); four patients in this group presented a serological reactivation and thus probably developed an acute infection during the study; two had a stable and moderate level of antibody throughout the study; in two patients the antibody titers decreased substantially. Interestingly, CD4 cell counts declined more rapidly in group 2 than in group 0 (medians of -4.5 versus -2.1 cells/mm3/month, p < 0.05 and -0.16 versus 0 cell percentage/month, p < 0.05), whereas there was no significant difference between groups 1 and 0 (medians of -2.0 versus -2.1 cells/mm3/month and -0.15 versus 0 cell percentage/month). In patients with serological reactivation, the viral load was higher in sera with higher M. penetrans antibody titers. These findings suggest an association between active M. penetrans infection and progression of HIV disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618077     DOI: 10.1089/aid.1998.14.661

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  The complete genomic sequence of Mycoplasma penetrans, an intracellular bacterial pathogen in humans.

Authors:  Yuko Sasaki; Jun Ishikawa; Atsushi Yamashita; Kenshiro Oshima; Tsuyoshi Kenri; Keiko Furuya; Chie Yoshino; Atsuko Horino; Tadayoshi Shiba; Tsuguo Sasaki; Masahira Hattori
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

2.  Role of Mycoplasma penetrans endonuclease P40 as a potential pathogenic determinant.

Authors:  M Bendjennat; A Blanchard; M Loutfi; L Montagnier; E Bahraoui
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Lipid extract of Mycoplasma penetrans proteinase K-digested lipid-associated membrane proteins rapidly activates NF-kappaB and activator protein 1.

Authors:  S H Feng; S C Lo
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

4.  Higher prevalence of urogenital mycoplasmas in human immunodeficiency virus-positive patients as compared to patients with other sexually transmitted diseases.

Authors:  C M Cordova; A Blanchard; R A Cunha
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

5.  Phase variation among major surface antigens of Mycoplasma penetrans.

Authors:  K Röske; A Blanchard; I Chambaud; C Citti; J H Helbig; M C Prevost; R Rosengarten; E Jacobs
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

6.  Alarming incidence of genital mycoplasmas among HIV-1-infected MSM in Jiangsu, China.

Authors:  J-R Wu; B Wang; L-S Chen; T Yang; L-J Zhou; Y-X Xie; J-S Xu; H-X Guo; X-P Huan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-15       Impact factor: 3.267

Review 7.  Mollicutes/HIV Coinfection and the Development of AIDS: Still Far from a Definitive Response.

Authors:  Caio Mauricio Mendes de Cordova; Caroline Galgowski; Leonardo Lange
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-06-16       Impact factor: 2.471

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.